肺复康合剂对肺纤维化大鼠病理变化的影响

Feifukang Mistura Treat Pulmonic Fibrosis of Rats in Pathology

目的探讨肺复康合剂对肺纤维化大鼠病理变化的影响。方法Wistar大白鼠110只随机分为正常组、模型组、中药Ⅰ组、中药Ⅱ组、西药组。除正常组外,其余四组复制肺纤维化动物模型。模型组用0.9%氯化钠注射液灌胃;中药Ⅰ组用肺复康合剂(1g/ml)灌胃;中药Ⅱ组用肺复康合剂(0.5g/ml)灌胃;西药组用强的松(0.17mg/ml)灌胃。各组于用药后28d及56d各随机处死一半大鼠取材送检。结果模型组大量胶原纤维增生,呈重度肺纤维化改变;中药Ⅰ组呈轻度肺纤维化;中药Ⅱ组病变程度较中药Ⅰ组略重;西药组病变程度较模型组轻,但较中药Ⅱ组为重。结论肺复康合剂可抑制成纤维细胞的活化和增殖,减少胶原纤维及非胶原蛋白的合成和分泌,抑制肺纤维化的发展。

Objective： To observe the pathology change of Feifukang Mistura treating pulmonic fibrosis. Methods： Wistar rats were divided into normal group, model group, TCM group Ⅰ, TCM group Ⅱ, WM group. Except the normal group, the other four groups were reproduced animal model of pulmonic fibrosis. The model group was given normal saline gavage. The TCM group Ⅰ was given Feifukang Mistura 1g/ml gavage. The TCM group Ⅱ was given Feifukang Mistura 0. 5g/ml gavage. The WM group was given prednisone gavage. Half rats of each group were taken lung to test in 28th, 56th day. Results： Large collagen fibers hyperplasia was founded in the model group. Mild pulmonary fibrosis was founded in the TCM group Ⅰ, fibrosis of the TCM group Ⅱ was more severe than the TCM group Ⅰ. Lesions of the WM group was milder than of the model group, but it was more severe than the TCM group Ⅱ. Conclusion： Feifukang Mistura could inhibit the activation and proliferation of fibroblast, reduce collagen fibers and non - collagen protein synthesis and secretion, inhibit the development of pulmonary fibrosis.